药物涂层球囊治疗膝下及腘动脉病变致严重肢体缺血的1年结果:西班牙Luminor注册研究
Luminor注册研究是一项IV期、非随机、前瞻性、观察性、多中心临床研究,纳入148例严重肢体缺血患者,分析Luminor® 14/14M和35药物涂层球囊治疗股腘及膝下病变的1年有效性与安全性。结果显示1年一期通畅率87.7%,免于临床驱动的靶病变血运重建率92.1%,生存率85.1%,免于大截肢率84.7%。
要点
- 严重肢体缺血患者使用Luminor药物涂层球囊1年一期通畅率达87.7%
- 1年免于临床驱动靶病变血运重建率为92.1%,免于大截肢率为84.7%
- 尽管患者合并症多、病情重,12个月结果在生存、保肢、通畅率和免于再干预方面令人满意
核心结论
- 在病情很重的严重肢体缺血人群中,Luminor药物涂层球囊12个月结果在生存、免于截肢、通畅率和免于再干预方面高度令人满意。
研究设计与样本
- Luminor注册研究为IV期、非随机、前瞻性、观察性、多中心临床研究,本分析纳入148例严重肢体缺血患者(101例男性,平均年龄73.2±11.4岁)。
- 治疗股腘动脉和膝下腘下动脉病变,术后、30天、6个月和12个月评估终点。
主要发现
- 平均随访11.2±3.27个月,1年一期通畅率为87.7%,免于临床驱动靶病变血运重建率为92.1%。
- 生存率为85.1%,免于大截肢率为84.7%。
- 83.3%患者为Rutherford 5级,糖尿病患病率71.6%,高血压87.2%,高脂血症57.4%,肾功能不全29.7%,冠心病39.2%。
临床怎么用
- 对于合并症多、病情重的严重肢体缺血患者,可考虑使用Luminor药物涂层球囊治疗股腘及膝下病变,1年通畅率和保肢率较好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Luminor is a new drug-coated angioplasty balloon, which is approved by the European Conformity market. The aim of the present study is to analyze the 1-year results, in terms of effectiveness and safety, of the Luminor® 14/14M and 35 drug-coated balloons (iVascular, Sant Vicenç dels Horts, Barcelona, Spain) in a special cohort of critical limb ischemia (CLI) of the Luminor registry. METHODS: Luminor is phase IV, nonrandomized, prospective, observational, and multicenter clinical study. The present study includes patients with CLI to analyze the effectiveness, in terms of primary patency, and the safety defined by the major adverse effects: any cause mortality, major amputation, and/or clinically driven target lesion revascularization (TLR). Both femoropopliteal and below-the-knee infrapopliteal lesions were treated. All the end points were assessed after the procedure, at 30 days, 6 and 12 months thereafter. RESULTS: About 148 patients (101 males; mean age, 73.2 ± 11.4 years) with CLI were included. About 83.3% were classified as Rutherford's class 5. Diabetes mellitus was diagnosed in 71.6%; hypertension, hyperlipidemia, renal insufficiency, and coronary disease were present in 87.2%, 57.4%, 29.7%, and 39.2% of the sample, respectively. The average follow-up was 11.2 ± 3.27 months. The primary patency and the freedom of clinically driven TLR, at 1 year, were 87.7% and 92.1%, respectively. Survival and freedom from major amputations were 85.1% and 84.7%, respectively. CONCLUSIONS: Even with a very sick population, the results at 12 months are highly satisfactory with reference to survival, freedom from amputation, patency, and the absence of reintervention.
引用
- Riambau V, Acín F, de Blas MJ, et al. Drug-Coated Balloon Angioplasty in Clinical Practice for Below-the-Knee, Popliteal, and Crural Artery Lesions Causing Critical Limb Ischemia: 1-Year Results from the Spanish Luminor Registry. Ann Vasc Surg. 2019. PMID: 31449955. doi:10.1016/j.avsg.2019.06.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。